Colon News and Research

RSS

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

30 Nov 2009

CCAC congratulates the Ontario government for expanding access to Avastin

The Colorectal Cancer Association of Canada (CCAC) applauds the Ontario Ministry of Health and Long-Term Care's decision today to provide expanded access of Avastin (bevacizumab) to patients with metastatic colorectal cancer.

30 Nov 2009

LCA-CA issues 2nd Annual Report Card on Lung Cancer

Today, Lung Cancer Alliance-California (LCA-CA) issued its 2nd Annual Report Card on Lung Cancer. The 2009 Report Card is an assessment of progress being made against this lethal disease in the state of California.

26 Nov 2009

LCA-GA issues 4th Annual Report Card on Lung Cancer

Today, Lung Cancer Alliance-Georgia (LCA-GA) issued the 4th Annual Report Card on Lung Cancer. This Report is an assessment of progress being made against this lethal disease in the state of Georgia.

26 Nov 2009

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.

26 Nov 2009

'Suicide gene E' reduces potent drug dosage in cancer patients

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

25 Nov 2009

New Brunswick's colorectal cancer screening program lauded by CCAC

The Colorectal Cancer Association of Canada (CCAC) applauds the decision of the New Brunswick's Minister of Health Mary Schryer to implement a province wide colorectal cancer screening program and to provide funding for Avastin (bevacizumab) for patients with metastatic colorectal cancer.

25 Nov 2009

Therapeutic agents in soy can treat colon cancer, says study

A study conducted by Children's Hospital & Research Center Oakland scientists identifies a new class of therapeutic agents found naturally in soy that can prevent and possibly treat colon cancer, the third most deadly form of cancer. Sphingadienes (SDs) are natural lipid molecules found in soy that research shows may be the key to fighting colon cancer.

24 Nov 2009

Medical Nutrition launches Diff-Stat pre- and probiotic supplement to prevent the onset of AAD and C-diff

Medical Nutrition USA, Inc., a developer and distributor of uniquely engineered, nutrition-medicine products, announced the introduction of Diff-Stat™, a new supplement containing pre- and probiotics to help restore and maintain beneficial bacteria that prevent the onset of antibiotic-associated diarrhea (AAD) and clostridium difficile (C-diff).

24 Nov 2009

LCA-NY issues 2009 Report Card on Lung Cancer

Today, Lung Cancer Alliance-New York (LCA-NY) issued its 1st Report Card on Lung Cancer. This Report is an assessment of progress being made against lung cancer in the state of New York. LCA-NY is a chapter of Lung Cancer Alliance (LCA), the only national organization dedicated exclusively to patient support and advocacy for people living with or at risk for lung cancer.

23 Nov 2009

Kingston University receives £99,000 for cancer research

Scientists have begun a three-year study to analyse why cancer patients become resistant to treatments designed to fight the disease. A research team from Kingston University has been awarded £99,000 to investigate why some tumours are sensitive and respond to treatments and why other tumours do not.

23 Nov 2009

BMI and co-morbidity do not explain racial survival disparity in colon cancer patients

A new study by University of Alabama at Birmingham (UAB) researchers shows that body-mass index (BMI) and co-existing medical conditions (co-morbidity) do not explain the decreased survival observed among African-Americans compared to Caucasians who also have colon cancer. The study is published online Nov. 23 in Cancer, a journal of the American Cancer Society.

23 Nov 2009

Given Imaging introduces new PillCam system at GASTRO 2009 Conference

Given Imaging Ltd., the global leader in capsule endoscopy, today announced the launch of its second-generation PillCam® COLON capsule at the Gastro 2009 Conference taking place in London. Like Given Imaging's other capsule endoscopes, PillCam® SB and PillCam® ESO, PillCam COLON could be a more patient-friendly tool for imaging the gastrointestinal tract.

23 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

Aperio Technologies receives U.S. patent for client/server image analysis

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,602,524 entitled "Image Processing and Analysis Framework."

19 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that preclinical results for CYT997 were presented today in a poster by Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.

17 Nov 2009

Hospitals should expand quality control guidelines to improve surgical complications in older patients

The elderly are more vulnerable to problems after a major surgical procedure than younger patients, but a team of investigators using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) suggest that one way to improve surgical results in this age group is to have hospitals expand their quality control guidelines to include more types of surgery-related complications.

17 Nov 2009

Targeting normal cells that surround cancer cells increases the effectiveness of traditional anti-cancer treatments

Targeting the normal cells that surround cancer cells within and around a tumor is a strategy that could greatly increase the effectiveness of traditional anti-cancer treatments, say researchers at The Wistar Institute.

17 Nov 2009

HealthPartners' health plans ranked top in Minnesota

HealthPartners is among the top 25 best private health plans in the nation and the top ranked plan in Minnesota according to U.S. News & World Report/NCQA “America's Best Health Insurance Plans 2009-10.” The report measures how well health plans perform on 50 measures of health care and member satisfaction. Two hundred thirty nine health plans from across the nation are included in the report. The top 50 health plans, including HealthPartners, are listed in the Nov. 16, 2009 print edition of U.S. News & World Report.

16 Nov 2009